BioSpace News Archive

ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA ® (loncastuximab tesirine-lpyl) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics announced that both pivotal trials for exagamglogene autotemcel in patients with transfusion-dependent beta thalassemia or severe sickle cell disease met primary and key secondary endpoints at pre-specified interim analyses.

Faron Pharmaceuticals Oy announces the release of new biomarker data from the ongoing Phase I/II BEXMAB study of bexmarilimab in combination with standard of care in the aggressive hematological malignancies of acute myeloid leukemia and myelodysplastic syndrome.

Immunovia AB announces that Jeff Borcherding, CEO of Immunovia, has purchased 350 000 shares for approximately 670 KSEK.

Invibio Biomaterial Solutions, part of Victrex plc, a pioneer in the development of PEEK biomaterial solutions, announced a new collaboration with Paragon Medical, a medical device contract design manufacturer with over a century of combined expertise in high-precision manufacturing, advanced engineering and design support, to manufacture composite PEEK-OPTIMA™ Ultra-Reinforced medical trauma devices.

Iovance Biotherapeutics, Inc. today announced that senior leadership plans to present at the Jefferies Global Healthcare Conference.

Praxis Precision Medicines , Inc. today announced the outcomes from a recent end-of-Phase 2 meeting with the U. S. Food and Drug Administration (FDA) regarding plans to advance ulixacaltamide into Phase 3 for essential tremor (ET).

Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (“Coeptis” or the “Company”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced today that it received approval from the Nasdaq Stock Market of the Company’s request to transfer its listing to the Nasdaq Capital Market from the Nasdaq Global Select Market.

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres Therapeutics management, will participate in a question and answer format discussion at the Goldman Sachs Global Healthcare Conference on Monday, June 12, 2023 at 4:40 p.m. PT.

U.S. Food and Drug Administration (FDA) Approves FoundationOne ® Liquid CDx as a Companion Diagnostic for Pfizer’s BRAFTOVI® (encorafenib) in Combination With Cetuximab to Identify Patients With BRAF V600E Alterations in Metastatic Colorectal Cancer.